Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,424,391
  • Shares Outstanding, K 73,487
  • Annual Sales, $ 57,990 K
  • Annual Income, $ -134,230 K
  • 60-Month Beta 2.05
  • Price/Sales 139.32
  • Price/Cash Flow N/A
  • Price/Book 7.30
Trade NTLA with:

Options Overview Details

View History
  • Implied Volatility 79.73%
  • Historical Volatility 60.64%
  • IV Percentile 39%
  • IV Rank 22.59%
  • IV High 142.93% on 12/21/20
  • IV Low 61.29% on 11/12/21
  • Put/Call Vol Ratio 0.77
  • Today's Volume 730
  • Volume Avg (30-Day) 594
  • Put/Call OI Ratio 2.11
  • Today's Open Interest 5,767
  • Open Int (30-Day) 4,206

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.89
  • Number of Estimates 9
  • High Estimate -0.64
  • Low Estimate -1.12
  • Prior Year -0.69
  • Growth Rate Est. (year over year) -28.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.34 +1.70%
on 12/03/21
143.92 -29.80%
on 11/08/21
-34.88 (-25.66%)
since 11/03/21
3-Month
99.34 +1.70%
on 12/03/21
180.59 -44.06%
on 09/07/21
-75.75 (-42.85%)
since 09/03/21
52-Week
40.10 +151.95%
on 12/04/20
202.73 -50.17%
on 06/30/21
+58.11 (+135.39%)
since 12/03/20

Most Recent Stories

More News
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered...

NTLA : 101.03 (-8.11%)
Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...

NTLA : 101.03 (-8.11%)
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -14.12% and -16.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for...

NTLA : 101.03 (-8.11%)
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escalation (Part 1) and initiation of...

NTLA : 101.03 (-8.11%)
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

XBI : 109.53 (-4.40%)
IBB : 148.39 (-1.88%)
BEAM : 68.02 (-6.26%)
AVXL : 17.03 (-5.60%)
FBT : 153.34 (-1.88%)
NTLA : 101.03 (-8.11%)
Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

XBI : 109.53 (-4.40%)
IBB : 148.39 (-1.88%)
BEAM : 68.02 (-6.26%)
AVXL : 17.03 (-5.60%)
FBT : 153.34 (-1.88%)
NTLA : 101.03 (-8.11%)
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...

NTLA : 101.03 (-8.11%)
Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag

Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.

REGN : 635.16 (+0.18%)
EDIT : 27.72 (-7.69%)
NTLA : 101.03 (-8.11%)
CRSP : 70.09 (-8.80%)
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...

NTLA : 101.03 (-8.11%)
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

Style Box ETF report for IWO

IWO : 283.43 (-2.70%)
LSCC : 74.25 (-1.59%)
CROX : 162.38 (-2.27%)
IJT : 131.85 (-1.41%)
NTLA : 101.03 (-8.11%)
VBK : 270.37 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with...

See More

Key Turning Points

3rd Resistance Point 118.23
2nd Resistance Point 114.12
1st Resistance Point 107.57
Last Price 101.03
1st Support Level 96.91
2nd Support Level 92.80
3rd Support Level 86.25

See More

52-Week High 202.73
Fibonacci 61.8% 140.61
Fibonacci 50% 121.41
Fibonacci 38.2% 102.22
Last Price 101.03
52-Week Low 40.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar